Geron Corporation (LON:0IV3)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 478.00M -7.9% |
| Revenue (ttm) | 163.84M +18.6% |
| Net Income | -36.03M |
| EPS | -0.06 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 13.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,876 |
| Open | 1.0000 |
| Previous Close | 0.9902 |
| Day's Range | 0.9603 - 1.0100 |
| 52-Week Range | 0.8469 - 1.9980 |
| Beta | 0.61 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Geron
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clini... [Read more]
Financial Performance
In 2025, Geron's revenue was $183.88 million, an increase of 138.83% compared to the previous year's $76.99 million. Losses were -$83.50 million, -52.17% less than in 2024.
Financial numbers in USD Financial StatementsNews
Geron Transcript: Stifel 2026 Healthcare Conference 2026
Quarterly revenue exceeded $60M after four consecutive quarters of growth, with community adoption and earlier-line use expanding. Priorities include a Germany commercial sale before year-end, disciplined spending, and business development after IMpactMF’s discontinuation.
Geron price target lowered to $3.50 from $4 at Stifel
Stifel lowered the firm’s price target on Geron (GERN) to $3.50 from $4 and keeps a Buy rating on the shares.
Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026
FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people liv...
Geron Earnings Call Transcript: Q3 2026
RYTELO revenue reached $60.1M, up 27% YoY, and management expects 2026 revenue toward the high end of guidance. European rollout begins in Germany, while IMpactMF was discontinued after the DMC judged it unlikely to meet its survival endpoint.
Geron Earnings release: Q3 2026
Geron released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Geron Quarterly report: Q3 2026
Geron has published its Q3 2026 quarterly earnings report on November 4, 2026.
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026
Geron Corporation to Participate in the Stifel 2026 Healthcare Conference
FOSTER CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood ca...
Geron price target lowered to $5 from $6 at Wedbush
Wedbush lowered the firm’s price target on Geron (GERN) to $5 from $6 and keeps an Outperform rating on the shares. The firm notes the company announced the discontinuation of…
Geron Slides: Corporate presentation
Geron has posted slides in relation to its latest quarterly earnings report, which was published on October 29, 2026.
Geron to discontinue IMpactMF trial
Geron (GERN) announced the decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis. This decision was based on a recommendation from...
Geron discontinues late-stage trial of blood cancer drug
Geron said on Wednesday it would discontinue a late-stage trial testing its treatment for patients with a form of rare blood cancer.
Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase ...
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood ca...
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood ca...
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced...
Geron Transcript: H.C. Wainwright 28th Annual Global Investment Conference
RYTELO has achieved record quarterly sales and is on track for $230–$240 million in 2026 revenue, driven by strong community adoption and expanding first- and second-line use. International expansion and pivotal myelofibrosis trial results are key upcoming catalysts.
Geron Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Revenue growth remains strong with guidance raised to $230–$240 million and profitability in sight. Expansion efforts target deeper community penetration and international markets, while a pivotal myelofibrosis trial advances with regulatory engagement.
Geron to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood c...
Geron Earnings Call Transcript: Q2 2026
Q2 2026 saw robust net revenue growth and expanding RYTELO adoption, with strong financial discipline and a solid cash position. Real-world evidence reinforced RYTELO's efficacy, and regulatory and commercial strategies are advancing in the U.S. and Europe.
Geron Earnings release: Q2 2026
Geron released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Geron Quarterly report: Q2 2026
Geron has published its Q2 2026 quarterly earnings report on August 5, 2026.
Geron reports Q2 EPS (2c), consensus (1c)
Reports Q2 revenue $57.48M, consensus $55.38M. “We are executing a focused strategy to build a leading hematology company, which starts with bringing RYTELO to more eligible patients impacted by LR-MD...
Geron sees FY26 revenue $220M-$240M, consensus $234.22M
The company said, “For fiscal year 2026, the Company expects RYTELO net product revenue to be in the range of $220 million to $240 million. Geron (GERN) also expects total…